PPD

OCTOBER 12, 2023

These treatments use a vector to introduce the desired nucleic acid code to replace or modify protein expression or use cells to alter/restore a specific cell type. There are over 2,000 CGTs currently being evaluated in clinical trials, with more than 200 in Phase III and 10-20 per year estimated to come to market by 2025.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

Conversations in Drug Development Trends

AUGUST 14, 2024

Proteomics Proteomics involves studying the entire set of proteins expressed in a cell or tissue. Check out our white paper to learn more about our services, or contact our team to find out how we can help support your oncology drug development program.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Conversations in Drug Development Trends

APRIL 7, 2025

Have you optimized your trial designs to employ precision medicine approaches for your novel solid tumor intervention? Integrate Biomarkers Where Possible Biomarker integration is crucial in solid tumor clinical trials, though more research is needed before fully validated assays become the norm across solid tumor indications.

Research 40

Research Clinical Trials Trials Clinical Research 40